Herbalife Ltd header image

Herbalife Ltd

HLF

Equity

ISIN KYG4412G1010 / Valor 2002103

CTA NASDAQ OMX Stock Exchange (2026-04-28)
USD 16.63+1.03%

Herbalife Ltd
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Herbalife Ltd. is a global nutrition company that operates primarily through a direct selling model, offering a range of products in areas such as weight management, sports nutrition, energy, and performance supplements. The company distributes its products via an extensive network of independent distributors across international markets, a model that emphasizes close ties with its consumer base. In recent years, the firm's leadership has focused on modernizing its sales training, deepening distributor engagement, and establishing strategic partnerships, all while transitioning toward a more agile, technology-driven global wellness platform. This strategic shift, led by Stephan Gratziani—who rose from a top-performing distributor to CEO—reflects the company's effort to maintain its long-term growth trajectory while adapting to evolving market dynamics.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (15.04.2026):

Herbalife Ltd reported results for the fourth quarter of 2025 showing continued momentum: Q4 net sales were $1.283 billion (up 6.3% vs. Q4 2024; +5.5% on a constant‑currency basis), with diluted EPS of $0.81 and adjusted diluted EPS of $0.45. Full‑year 2025 net sales were $5.0375 billion (up 0.9%; +2.5% constant currency), adjusted EBITDA expanded to $657.6 million, and the company ended the year with a total leverage ratio of 2.8x. The company also announced a strategic investment in its Pro2col platform by Cristiano Ronaldo in February 2026.

Quarterly sales and margins

Q4 2025 net sales: $1,283.0M (+6.3% YoY; +5.5% ex‑FX). Gross profit margin was 77.5% (vs. 77.8% a year ago), with FX, mix and input cost pressures largely offset by pricing and freight benefits.

Profitability and non‑GAAP metrics

Q4 net income attributable to Herbalife: $85.4M (net income margin 6.7%). Q4 adjusted net income: $47.5M. Q4 adjusted EBITDA: $156.1M (12.2% margin); on a constant‑currency basis adjusted EBITDA was $167.7M. Diluted EPS: $0.81; adjusted diluted EPS: $0.45 (includes FX headwind).

Full‑year 2025 results

FY 2025 net sales: $5,037.5M (+0.9% YoY; +2.5% constant currency). FY net income attributable: $228.3M; adjusted net income: $219.4M. FY adjusted EBITDA: $657.6M (or $713.9M constant currency). Net cash provided by operating activities: $333.3M for the year.

Regional performance and distributors

Q4 regional highlights: North America $243.1M (‑0.8% YoY), Latin America $234.7M (+17.6% YoY; +11.0% ex‑FX), EMEA $280.9M (+9.2%), Asia Pacific $461.3M (+4.9%), China $63.0M (‑4.4%). North America posted double‑digit new distributor growth (+19% YoY); worldwide new distributors were down 5% YoY but up 16% on a two‑year stack.

Cash, capex and capital structure

Q4 operating cash flow: $98.3M; FY capex: $80.4M (Q4 capex $18.5M). Revolving credit facility undrawn at year‑end (vs. $25M outstanding in Sep 2025). Total leverage ratio per the credit agreement: 2.8x as of Dec 31, 2025.

Pro2col and recent developments

In February 2026 Cristiano Ronaldo invested $7.5M for a 10% equity stake in HBL Pro2col Software, LLC and committed sponsorship/services. The company made contingency payments of $3.0M in Q4 (and $5.0M for the year) related to Pro2col beta milestones.

Outlook (guidance)

Q1 2026 guidance: reported net sales +3.0% to +7.0% YoY (constant currency +0.5% to +4.5%); adjusted EBITDA $155–$175M; capex $10–$20M. Full‑year 2026 guidance: reported net sales +1.0% to +6.0% YoY (constant currency +0.0% to +5.0%); adjusted EBITDA $670–$710M; capex $50–$80M. Management also flagged $40–$60M of capitalized SaaS implementation costs (not in capex) and an adjusted tax rate ~30%.

Summarized from source with an LLMView Source

Key figures

141%1Y
11.9%3Y
-63.5%5Y

Performance

62.8%1Y
63.6%3Y
59.9%5Y

Volatility

Market cap

1719 M

Market cap (USD)

Daily traded volume (Shares)

1,197,079

Daily traded volume (Shares)

1 day high/low

6.83 / 6.6

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Progyny Inc
Progyny Inc Progyny Inc Valor: 50342281
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.16%USD 18.38
Ste Virbac SA
Ste Virbac SA Ste Virbac SA Valor: 524407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.88%EUR 366.00
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Amphastar Pharmaceuticals Inc Valor: 24511852
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.79%USD 21.82
Trupanion Inc
Trupanion Inc Trupanion Inc Valor: 24738737
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-8.40%USD 24.96
SOLVENTUM CORP
SOLVENTUM CORP SOLVENTUM CORP Valor: 133635906
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.25%USD 67.51
Agenus Inc
Agenus Inc Agenus Inc Valor: 134326284
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.89%USD 3.89
Edgewise Therapeutics Inc
Edgewise Therapeutics Inc Edgewise Therapeutics Inc Valor: 110444153
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.14%USD 30.99
EssilorLuxottica SA
EssilorLuxottica SA EssilorLuxottica SA Valor: 497537
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.01%EUR 182.70
ImmunityBio Inc
ImmunityBio Inc ImmunityBio Inc Valor: 110468647
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.53%USD 6.96
Tempus AI Inc
Tempus AI Inc Tempus AI Inc Valor: 135855934
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.00%USD 51.10